ResearcherAffiliated Hospital of Nantong UniversityActive in the last 2 years

Dongzhi Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5144042650. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 1 paper

Papers 1

MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid reprogramming. Last author DOI 10.1016/j.jconrel.2026.115223 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yan Xue · 1 shared paper, 2026 · strength 0.30
- Paper MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid re… DOI 10.1016/j.jconrel.2026.115223 ↗
Yibing Guo · 1 shared paper, 2026 · strength 0.30
- Paper MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid re… DOI 10.1016/j.jconrel.2026.115223 ↗
Xingyu Jiang · 1 shared paper, 2026 · strength 0.30
- Paper MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid re… DOI 10.1016/j.jconrel.2026.115223 ↗
Yuhua Lu · 1 shared paper, 2026 · strength 0.30
- Paper MβCD@HA-Ad nanoparticles inhibit pancreatic cancer progression by targeting Caveolin-1/Piezo1/PLA2G4A-mediated lipid re… DOI 10.1016/j.jconrel.2026.115223 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.